Companies /Healthcare

Abbott Laboratories

NYSE: ABT Medical Devices
$111.76
▼ $2.34 (−2.05%) today
Markets open · 3:18pm ET

Q2 2026 Earnings

Reported Jul 16, 2026, 7:36am ET · SEC source
$1.31
Beat +2.63%
EPS · est. $1.28
$12.6B
Beat +0.62%
Revenue · est. $12.5B
+8.8%
Beating market
ABT vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+4%+8%Jul 16Jul 17report 7:36am ETearnings−1.0%+8.3%
0+4%+8%Jul 16Jul 17earnings−1.0%+8.3%
ABT +8.3%S&P 500 −1.0%
0+5%+10%Jul 16Jul 17report 7:36am ETearnings−1.6%+8.3%
0+5%+10%Jul 16Jul 17earnings−1.6%+8.3%
ABT +8.3%NASDAQ −1.6%
0+5%+10%Jul 15Jul 24report 7:36am ETearnings−1.6%+10.7%
0+5%+10%Jul 15Jul 24earnings−1.6%+10.7%
ABT +10.7%S&P 500 −1.6%
0+5%+10%Jul 15Jul 24report 7:36am ETearnings−2.5%+10.7%
0+5%+10%Jul 15Jul 24earnings−2.5%+10.7%
ABT +10.7%NASDAQ −2.5%
+10.71%
Day of report
+1.87%
Next session
+1.94%
One week
+11.68%
30 days

S&P 500 over the same 30 days: +2.92%.

Did ABT Beat Earnings? Q2 2026 Results

Abbott Laboratories delivered a clean beat to open its second quarter of 2026, posting adjusted diluted EPS of $1.31 against a consensus estimate of $1.28, a 2.63% beat that extended the company's streak of topping Wall Street's earnings expectations to five consecutive quarters. Revenue of $12.59 billion grew 13.0% year over year, edging past the $12.52 billion consensus by 0.62%, with the transformative acquisition of Exact Sciences, completed in March, providing the primary engine behind the reported top-line surge. On a comparable basis that folds Exact Sciences into the prior-year base, sales rose a more measured 4.8%, with Medical Devices leading the way at $5.85 billion, up 9.0% reported, fueled by strong Electrophysiology and Diabetes Care momentum. Competitive pressures in continuous glucose monitoring remained a watchpoint for investors, but Abbott's performance gave management confidence to raise full-year adjusted EPS guidance to $5.45 to $5.60 while reaffirming comparable sales growth of 6.5% to 7.5%, with third-quarter adjusted EPS guided at $1.38 to $1.46.

Key Takeaways
  • Medical Devices led by low-teens Electrophysiology growth and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure
  • Continuous glucose monitor sales grew 11.0% reported and 9.5% comparable
  • Diagnostics boosted by Exact Sciences acquisition adding Cancer Diagnostics sub-segment with $919 million in Q2 sales
  • Cologuard delivered mid-teens growth benefiting from growing base of new and repeat users
  • Established Pharmaceuticals Key Emerging Markets grew 10.7% comparable led by double-digit growth in Latin America and Asia Pacific
  • Core Laboratory Diagnostics driven by strong growth in U.S. and Latin America
  • Cancer Diagnostics U.S. sales of $890 million represented 96.8% of segment revenue, growing 13.3% comparable
  • Diagnostics U.S. sales surged 104.8% reported driven by Exact Sciences contribution

“Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”

Abbott Laboratories CEO, on the earnings call

Forward Guidance & Outlook

Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5%. The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up from the previous range of $5.38 to $5.58. For Q3 2026, Abbott projects adjusted diluted EPS of $1.38 to $1.46. Management expects momentum to continue and drive accelerating sales and earnings growth in the second half of the year.

ABT YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$4.0B$8.0B$12.0B$11.1B$12.6BRevenue$6.3B$6.6BGross Profit$2.1B$1.7BOperating Income$1.8B$928.0MNet Income
$0$4.0B$8.0B$12.0BRevenueGross ProfitOperating IncomeNet Income

ABT Revenue by Segment

Medical Devices$5.9B+9.0%
Diagnostics$3.1B+42.3%
Nutrition$2.1B−3.1%
Continuous Glucose Monitors$2.2B+10.5%
Diabetes Care
Established Pharmaceuticals$1.5B+8.4%
Core Laboratory Diagnostics
Adult Nutrition$1.1B−3.4%

ABT Revenue by Geography

Rest of World$7.4B+7.5%
United States$5.2B+22.0%

Figures from SEC filings and company reports. Not investment advice.